



DT03 PCT/PTO

11 FEB 2005

CASE 1-32411A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV540157186 U.S.

Express Mail Label Number

2-11-05

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
CHIQUET-EHRISMANN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/003150

FILED: 26 MARCH 2003

U.S. APPLICATION NO: 10/509,009

35 USC §371 DATE:

FOR: TENASCIN-W COMPOSITIONS AND USES THEREOF

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report. Since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

References with a double asterisk (***) were cited in the UK Search Report, and copies of those references are also enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



John T. Prince
Attorney for Applicants
Reg. No. 43,019

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346

Date: February 11, 2005

INFORMATION DISCLOSURE CITATION

O I P E (Use several sheets if necessary)



Sheet 1 of 5

ATTY. DOCKET NO.
1-32411A
APPLICATION NO.
10/509,009
APPLICANT
CHIQUET-EHRISMANN ET AL.
FILING DATE
SEPTEMBER 24, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	6,124,260		Sharifi, et al.			
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
AM	WO 9421293		PCT			<input type="checkbox"/>	<input type="checkbox"/>
AN	WO 9204464		PCT			<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Arakawa, et al. "Mus Musculus 16 Days Embryo Head cDNA", Database EMBL Online; Accession No. BB648643 - XP002250801 (2001)*
AS	Zhao, et al. "RPCI-24-112D17.TV RPCI-24 Mus Musculus Genomic Clone RPCI-24-112D17", Database EMBL Online, Accession No. AZ748340 XP002250802 (2001) *
AT	Rhodes, S., "Novel Human mRNA from Chromosome 1, Similar to Tenascin-R", Database EMBL Online, Accession No. AL049689 (1999) *

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2

ATTY. DOCKET NO.

1-32411A

APPLICATION NO.

10/509,009

APPLICANT

CHIQUET-EHRISMANN ET AL.

FILING DATE

SEPTEMBER 24, 2004

Group

EXAMINER INITIAL


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Abe, et al., "Purification of Primordial Germ Cells from TNAP Bgeo Mouse Embryos Using FACS-gal", Develop. Biol., Vol. 180, pp. 468-72 (1996)
	DB	Akamatsu, et al., "Suppression of Transformed Phenotypes of Human Fibrosarcoma Cells by Overexpression of Recombinant Fibronectin", Cancer Res., Vol. 56, pp. 4541-46 (1996)
	DC	Bloom, et al., "Fibronectin Regulates Assembly of Actin Filaments and Focal Contacts in Cultured Cells Via the Heparin-binding Site in Repeat III 13", Mol. Biol. of the Cell, Vol. 10, pp. 1521-36 (1999)
	DD	Boudreau, et al., "Extracellular Matrix Signaling: Integration of Form and Function in Normal and Malignant Cells", Current Opin. in Cell Biol., Vol. 10, pp. 640-46 (1998)
	DE	Bourdon, et al., "Human Glioma-mesenchymal Extracellular Matrix Antigen Defined by Monoclonal Antibody", Cancer Res., Vol. 43, pp. 2796-2805 (1983)
	DF	Burch, et al., "Tenascin-X Deficiency Is Associated with Ehlers-Danlos Syndrome", Nature Gen., Vol. 17, pp. 104-8 (1997)
	DG	Chiquet, et al., "Chick Myotendinous Antigen II. A Novel Extracellular Glycoprotein Complex Consisting of Large Disulfide-linked Subunits", J. of Cell Biol., Vol. 98, pp. 1937-46 (1984)
	DH	Chiquet, et al., "Chick Myotendinous Antigen I. A Monoclonal Antibody as a Marker for Tendon and Muscle Morphogenesis", J. of Cell Biol., Vol. 98, pp. 1926-36 (1984)
	DI	Chiquet-Ehrismann, "Tenascins, A Growing Family of Extracellular Matrix Proteins", Experientia, Vol. 51, pp. 853-62 (1995)
	DJ	Chiquet-Ehrismann, "Tenascin and Other Adhesion-modulating Proteins in Cancer", Cancer Biol., Vol. 4, pp. 301-10 (1993)
	DK	Chiquet-Ehrismann, et al. "Tenascin: An Extracellular Matrix Protein Involved in Tissue Interactions During Fetal Development and Oncogenesis", Cell, Vol. 47, pp. 131-39 (1986)
	DL	Chiquet-Ehrismann, et al., "Tenascin Interferes with Fibronectin Action", Cell, Vol. 53, pp. 383-90 (1988)
	DM	Denda, et al. "Utilization of a Soluble Integrin-alkaline Phosphatase Chimera to Characterize Integrin α8/B1 Receptor Interactions with Tenasin: Murine α8/B1 Binds to the RGD Site in Tenascin-C Fragments, but Not to Native Tenascin-C", Biochem., Vol. 37, pp. 5464-74 (1998)
	DN	Erickson, et al., "A Six-armed Oligomer Isolated from Cell Surface Fibronectin Preparations", Nature, Vol. 311, pp. 267-69 (1984)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

1-32411A
APPLICATION NO.
10/509,009
APPLICANT
CHIQUET-EHRISMANN ET AL.
FILING DATE
SEPTEMBER 24, 2004

Sheet 3

Group

EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Huse, et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science, Vol. 246, pp. 1275-81 (1989)
	DB	Kohfeldt, et al., "Properties of the Extracellular Calcium Binding Module of the Proteoglycan Testican", FEBS, Vol. 414, pp. 557-61 (1997)
	DC	Kohler, et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", Nature, Vol. 256, pp. 495-97 (1975)
	DD	Koyama, et al., "Expression of Syndecan-3 and Tenascin-C: Possible Involvement in Periosteum Development", J. of Ortho. Res., Vol. 14, pp. 403-12 (1996)
	DE	Latijnhouwers, et al., "Tenascin Expression During Wound Healing in Human Skin", J. of Path., Vol. 178, pp. 30-35 (1996)
	DF	Li, et al., "Expression of Stromelysin-1 and TIMP-1 in the Involuting Mammary Gland and in Early Invasive Tumors of Mouse", Int. J. Cancer, Vol. 59, pp. 560-68 (1994)
	DG	Munarini, et al., "Altered Mammary Epithelial Development, Pattern Formation and Involution in Transgenic Mice Expressing the EphB4 Receptor Tyrosine Kinase", J. of Cell Science, Vol. 115, pp. 25-37 (2002)
	DH	Giancotti, et al. "Elevated Levels of the a5B1 Fibronectin Receptor Suppress the Transformed Phenotype of Chinese Hamster Ovary Cells", Cell, Vol. 60, pp. 849-59 (1990)
	DI	Hagios, et al., "Tenascin-Y: A Protein of Novel Domain Structure Is Secreted by Differentiated Fibroblasts of Muscle Connective Tissue", J. of Cell Biol., Vol. 134, pp. 1499-1512 (1996)
	DJ	Hall, et al., "Divid, Accumulate, Differentiate: Cell Condensation in Skeletal Development Revisited", Int. J. Dev. Biol., Vol. 39, pp. 881-93 (1995)
	DK	Ward, et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia Coli", Nature, Vol. 341, pp. 544-46 (1989)
	DL	Weber, et al., "Zebrafish Tenascin-W, a New Member of the Tenascin Family", Swiss Fed. Inst. Of Tech., Zurich, pp. 1-16 (1997)
	DM	Yokosaki, et al., "Differential Effects of the Integrins a9B1, avB3, and avB6 on Cell Proliferative Responses to Tenascin", J. of Biol. Chem., Vol. 271, pp. 24144-50 (1996)
	DN	Yokosaki, et al., "Identification of the Ligand Binding Site for the Integrin a9B1 in the Third Fibronectin Type III Repeat of Tenascin-C", J. of Biol. Chem., Vol. 273, pp. 11423-28 (1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FEB 11 2005

EXAMINER INITIAL

ATTY. DOCKET NO.
1-32411A
APPLICATION NO.
10/509,009
APPLICANT
CHIQUET-EHRISMANN ET AL.
FILING DATE
SEPTEMBER 24, 2004Sheet 4
Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Neidhardt, et al. "Tenascin-N: Characterization of a Novel Member of the Tenascin Family that Mediates Neurite Repulsion from Hippocampal Explants", Mol. and Cell. Neuro., Vol. 23, pp. 193-209 (2003)*
	DB	Neidhardt, et al. "Mus Musculus Tenascin-N (tnn) mRNA", Database EMBL Online, Database Accession No. AF455756 (2002) *
	DC	Adachi, et al., "Mus Musculus 16 Days Embryo Head cDNA", Database EMBL online, Database Accession No. AK048033 (2002) *
	DD	Philipp, et al., "Zebrafish Tenascin-W, a New Member of the Tenascin Family", J. of Neurobiology, Vol. 35, pp. 1-16 (1998) *
	DE	
	DF	Mackie, et al., "Induction of Tenascin In Wound Healing", J. Cell. Biol., Vol. 107, pp. 2757-67 (1988) [TO BE PROVIDED]
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



FEB 11 2005

FORM 1449 (5-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 5

ATTY. DOCKET NO.
1-32411A
APPLICATION NO.
10/509,009
APPLICANT
CHIQUET-EHRISMANN ET AL.
FILING DATE
SEPTEMBER 24, 2004

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Hauptmann, et al. "Extracellular Matrix Proteins in Colorectal Carcinomas", Lab. Invest., Vol. 73 (1995)
	DB	Jones, et al., "The Tenascin Family of ECM Glycoproteins: Structure, Function, and Regulation During Embryonic Development and Tissue Remodeling", Dev. Dynamics, Vol. 218 (2000)
	DC	Norderhaug, et al., "Versatile Vectors for Transient and Stable Expression of Recombinant Antibody Molecules in Mammalian Cells", J. of Imm. Meth., Vol. 204 (1997)
	DD	Pesheva, et al., "Tenascin-R as a Regulator of CNS Glial Cell Function", Prog. in Brain Res., Vol. 132 (2001)
	DE	Raouf, et al., "Discovery of Osteoblast-associated Genes Using cDNA Microarrays", Bone, Vol. 30 (2002)
	DF	Riva, et al, "Loco-regional Radioimmunotherapy of High-grade Malignant Gliomas Using Specific Monoclonal Antibodies Labeled with 90Y: A Phase I Study", Clin. Can. Res., Vol. 5 (1999)
	DG	Riva, et al., "131I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of High-grade Malignant Glioma", Acta Onc., Vol. 38 (1999)
	DH	Ruoslahti, "Fibronectin and Its Integrin Receptors in Cancer", Advances in Cancer Res. (1999)
	DI	Schenk, et al., "Tenascin-C in Serum: A Questionable Tumor Marker", Int. J. Cancer, Vol. 61 (1995)
	DJ	Zalutsky, et al., "High-level Production of a-Particle-Emitting 211 At and Preparation of 211 At-Labeled Antibodies for Clinical Use", J. of Nuc. Med., Vol. 42 (2001)
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.